p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules

Ananthan Sadagopan,Nicholas Garaffo,Heng-Jui Chang,Stuart L Schreiber,Matthew Meyerson,William J Gibson

DOI: https://doi.org/10.1101/2024.07.27.605429

2024-07-27

Abstract:TP53 mutant cancers are associated with approximately half of cancer deaths. The most common mechanism of p53 inactivation involves missense mutations. Such mutations in TP53 result in a robust upregulation of the p53 protein. Here, we demonstrate an induced proximity approach to selectively kill TP53 mutant cells. This approach uses the increased abundance of p53 protein in TP53 mutant cancer cells to concentrate toxic molecules in these cells. We demonstrate the first generalizable strategy using a small molecule to selectively kill TP53 mutant cells. This molecule binds the Y220C mutant of p53 and concentrates a PLK1 inhibitor in cells harboring TP53 Y220C mutations. Together, these data demonstrate that the abundance of p53 protein provides a therapeutic window for TP53 missense mutant cancers that can be translated into a cell death signal using proximity-inducing small molecules.

Biochemistry

What problem does this paper attempt to address?

The main objective of this paper is to develop a universal strategy to specifically kill cancer cells carrying TP53 mutations using small molecule drugs. Specifically, the research team focused on missense mutations in the TP53 gene, which lead to abnormal accumulation of the p53 protein. They proposed an induced proximity approach by designing bifunctional small molecules to exploit this overexpression of the p53 protein.

Key findings described in the paper include:
1. **Overexpression of p53 protein**: Unlike most tumor suppressor genes, TP53 mutations usually manifest as missense mutations, leading to abnormal accumulation of the p53 protein.
2. **No synthetic lethality interactions**: Large-scale functional genomics studies have shown that no specific genes exhibit synthetic lethality interactions in cancer cells with TP53 mutations.
3. **Overexpression of p53 protein as a therapeutic window**: The authors utilized the overexpression of p53 protein in TP53 mutant cancers as a therapeutic opportunity to develop small molecules that can specifically target these cells.
4. **Design of bifunctional small molecules**: By combining p53 protein and toxic molecules, bifunctional small molecules can specifically kill cancer cells with high concentrations of p53 protein.
5. **Small molecules targeting specific p53 mutations**: The study particularly focused on the p53Y220C mutation and developed small molecules that can selectively kill cells carrying this mutation.

In summary, this paper aims to address how to exploit the overexpression of p53 protein in TP53 mutant cancers to develop small molecule drugs that can specifically kill these cancer cells.